The role of acute anticoagulation in ischaemic cerebrovascular disease is complex. It is well established with respect to preventing further embolization in cardiogenic cerebral embolism 4, 8, 11 .
When there is occlusive disease of the supra-aortic or intra-cranial vessels producing thromboembolism of the brain, and specially in cases in which surgery is not recommended, the risk/benefit ratio is not well defined.
No controlled studies of the efficacy or of the rate of complications of acute anticoagulation in cerebro-vascular disease have been reported since the advent of computerized axial tomography. The earlier studies became obsolete since it became clear that this method detects ischaemic and haemorrhagic infarction as well as hematomas, avoiding use of anticoagulants in haemorrhagic disease 12 .
Although aspirin has been demonstrated to be efficient in the prevention of recurrence of transient ischaemic attacks 5, 8 , the physician admitting a patient with the recent onset of a stable or a fluctuating vascular neurological deficit will be in difficulty to decide on the utilization of anticoagulation. Transient ischaemic attacks of recent onset, for example, may be followed by a completed stroke, the greatest risk occurring in the first week 10 .
The time between admission and the completion of the full work up needed by such patients, which includes cardiac and vascular investigations not immediately available at all hospitals, is usually of the order of days rather than hours.
On the other hand computerized axial tomography is becoming very common all over the world and may be carried out soon after the patient is admitted, without any worsening of prognosis.
In this study we have evaluated the risk of complications of a simple method of administration of heparin to patients with acute ischaemic cerebro vascular disease, specifically with respect to age and arterial hypertension, which have been traditionally considered to be contra-indications for anticoagulant use. Heparin regimen -The clearence of heparin from the blood stream is exponential and dose-dependent. The half-life at dosages of 100 IU per kilogram is around 152 minutes 7.
It thus follows that intermittent regimens in which 5000 IU are given at intervals of 4 or 6 hours will produce a very high blood level for between one and two hours, when the coagulation time is infinite and the risk is very high 7. In fact it has been demonstrated that the frequency of serious bleeding during intermittent administration is above 10%
13 .
In con tinuous infusion the peaks in blood level are avoided, decreasing serious bleeding to about 1 % 13 . Deykin reviewed a number of studies on the complications and efficacy of heparin regimens 2 .
In a prospective study carried out by his group 72 patients were given intermittent intravenous injection regulated by activated partial thromboplastin time (APTT); 68 patients were given inter mittent intravenous injection with fixed doses; a further group of 69 patients were given intravenous infusion with the dose regulated by APTT.
The mean heparin dose was 31700IU in the first group, 35600IU in the second group and 24500IU in the third group.
Recurrences occurred in one case in each group. Major bleeding complications occurred in 6 patients in the first group, 7 in the second and one patient in the third group. Measuring the efficacy of anti-coagulation by the recurrence rate there is no difference in the three regimens.
Considering the number of bleeding complications as evidence of peaks of intermittent anticoagulation continuous infusion is the better regimen. It should be emphasized that there is a great difference of dose between the three regimens, and that the lesser number of complications with continuous infusion may also be related to the dose utilized, which was % of the two other regimens.
Since infusion pumps are not generally avaiable in general hospitals in less developed countries we decided to use a safe and simple approach, i.e., to give intravenously a total dose of 20000 IU daily, divided in doses of 2500 IU every three hours. 
PATIENTS AND METHODS

All patients admitted to the
COMMENTS
Full immediate anticoagulation in cardiogenic cerebral embolism has been demonstrated to be safe if a haemorrhagic component is excluded by compu terized axial tomography 9.
The present study supports such findings since there were no complications in 22 patients with cardiogenic cerebral embolism. With respect to the efficacy of the regimen these results confirm previous findings 2,13 that close monitoring of coagulation tests may not be critical, since in the two cases in whom further cardiogenic embolization was diagnosed clinically raising of the dose of heparin was efficient in terminating the episodes.
The efficacy of the regimen advocated here, i.e., 20000 IU daily divided in three hourly intravenous injections is more difficult to evaluate in the remaining 28 patients with cerebral ischaemia due to supra-aortic or intra-cranial thrombo-embolic phenomena, because the rate of re-embolization or the course of the neurological deficit is less predictable. The risk of non-cardiac recurrent transient ischaemic attacks developing into completed strokes is highest in the first week 10.
None of the patients with transient ischaemic attacks in this study developed a completed stroke while on heparin. In fact the only vascular event in non-cardiogenic embolism was deep venous thrombosis in a severely fractured lower limb. At any rate the regimen proposed here did not produce major bleeding complications as reported in previous studies 3,6,14
Correct evaluation of the risk/benefit ratio of anticoagulation in acute ischaemic cerebro-vascular disease due to thromboembolic phenomena of supra--aortic or intra-cranial arteries will need a controlled study in which a group of patients does not receive anticoagulation.
Nonetheless, the results of the present study suggest that a regimen of 2500 IU of heparin given intravenously every three hours is safe in all kinds of acute ischaemic cerebro-vascular disease, without close monitoring of coagulation tests.
It should be emphasized that this was demonstrated in a group of 50 patients which included 17 cases with blood pressures above 160/95 at the start of therapy as well as 13 patients above 65 years of age.
It is thus suggested that old age, and moderate or severe hypertension do not formally contra-indicate anticoagulation, if reasonable control of blood pressure is achieved within a few hours. We thus recommend that 2500 IU of heparin given intravenously every 3 hours is used in the treatment of acute cerebral ischaemia of any kind, if a haemorrhagic component can be excluded by computerized axial tomography, unless continuous infusion and clotting monitoring are available routinely to the large numbers of such patients admitted to general hospitals.
SUMMARY
The risk/benefit ratio of acute anticoagulation in ischaemic cerebro-vascular disease is not clearly established.
A simple and safe intermittent intravenous heparin regimen (20000 IU daily) was used prospectively in 50 patients of 57 ± 14 (m ± sd) years of age whose blood pressures ranged from normal to severe hypertension. Twenty-two patients had cardiogenic embolism and the remaining had recurrent severe transient ischaemic attacks of recent onset or progressive cerebral infarcts. Time of exposure to heparin was 6.4 ± 4 (m±sd) days.
Two patients had recurrences of cerebral thromboembolism and none had bleeding complications. This is a safe and efficient method of anticoagulation for patients with cerebral ischaemia when continuous infusion of heparin or close monitoring of clotting times are not used routinely.
RESUMO
Regime simples e seguro de heparina para isquemia aguda.
A relação entre risco e benefício de anticoagulação imediata em doença cerebrovascular isquêmica é discutível. Um regime simples e seguro de administração endovenosa de heparina (20000 IU/dia) foi utilizado prospectivamente em 50 pacientes de 57 ± 14 (média ± desvio padrão) anos de idade cujas pressões arteriais variaram de normais a hipertensão severa.
Vinte e dois dos pacientes sofreram embolia cerebral cardiogênica e o restante ataques isquê-micos transitórios de início recente ou infartos cerebrais progressivos. O tempo de exposição à heparina foi de 6,4 ± 4 (média ± desvio padrão) dias. Dois pacientes tiveram recorrência de tromboembolismo cerebral e nenhum teve complicações hemorrágicas. Este parece ser um método seguro e eficiente de anticoagulação para pacientes com isquemia cerebral aguda, quando infusão contínua de heparina ou monitorização de testes de coagulação frequente não são usados rotineiramente.
